Market closedNon-fractional

Compass Therapeutics/CMPX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Compass Therapeutics

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Ticker

CMPX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

32

CMPX Metrics

BasicAdvanced
$110M
Market cap
-
P/E ratio
-$0.35
EPS
0.73
Beta
-
Dividend rate
$110M
0.73
40.743
40.137
0.12
0.9
-19.13%
-27.35%
0.7
0.7
-2.45
-1.94%
-21.67%

What the Analysts think about CMPX

Analyst Ratings

Majority rating from 7 analysts.
Buy

CMPX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
-20.15%
Profit margin
0.00%
NaN%

CMPX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 29.11%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.09
-$0.08
-$0.11
-$0.08
-
Expected
-$0.08
-$0.11
-$0.09
-$0.11
-$0.09
Surprise
10.53%
-25.33%
16.84%
-29.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Compass Therapeutics stock?

Compass Therapeutics (CMPX) has a market cap of $110M as of July 06, 2024.

What is the P/E ratio for Compass Therapeutics stock?

The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of July 06, 2024.

Does Compass Therapeutics stock pay dividends?

No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Compass Therapeutics dividend payment date?

Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.

What is the beta indicator for Compass Therapeutics?

Compass Therapeutics (CMPX) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Compass Therapeutics stock

Buy or sell Compass Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing